Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus PHENETRON.
ACTAHIST vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
1.34 mg (one capsule) orally twice daily.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine
Antihistamine